Contribute Try STAT+ Today

For the eighth consecutive year, the credit outlook for the pharmaceutical industry is negative and more drug makers should expect that their credit ratings may fall this year, according to a new forecast from S&P Global Ratings.

The ratings agency cites three key reasons for the downbeat view. The first is the expectation that mergers and acquisitions will continue apace as drug companies seek to bolster their pipelines. But deals are often paid for, at least in part, with debt. And as S&P sees it, more debt “nearly always outweighs the incremental benefits.” In the past, M&A has been the chief contributor to downgrades, which numbered 20 between 2014 and 2020, compared with three upgrades.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.